ClinicalTrials.gg
Not yet recruitingNCT07942324Updated Nov 17, 2026

Conversational Memory in Aging and AD

An interventional study of Verbal Summary and Written Summary in Alzheimer Dementia (AD) and Mild Cognitive Impairment (MCI) Amnestic, sponsored by New York University. Not yet recruiting at 1 site in United States. Open to participants aged 65 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by New York University · Not applicable, Interventional, and Basic science

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
65 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
529th of 1,611
150 · median 73
Started
2027
with 8 others
No phase
611 of 1,942
133 open now
Primary completion
2031-05
later than 426 of 446 live
Registered
1,942nd of 1,942
by date

Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 529th largest by planned enrollment of the 1,611 interventional ones that give a count, is one of 9 that started in 2027, is one of 611 with no phase, reaches primary completion later than 426 of the 446 other live ones, and was the 1,942nd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

343 more — sign in →

All 348 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 65 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,942 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This study examines how conversational engagement and different forms of communication support affect memory in older adults with and without mild cognitive impairment (MCI) or mild Alzheimer's disease (AD). Participants will complete conversational and memory tasks, including simulated health-related conversations, across five study visits. The study will compare how actively generating information during conversation and receiving verbal or written communication support influence immediate and delayed memory. It will also examine how individual differences in cognitive abilities and visual attention are associated with memory for information exchanged during conversation. Findings from this study may help identify communication strategies that support everyday memory and communication in older adults experiencing cognitive decline.

Read the detailed description

Effective everyday communication requires individuals not only to understand information provided by others but also to actively contribute to and remember information exchanged during conversation. Active participation in conversation may enhance subsequent memory because generating information can produce stronger memory representations than passively receiving the same information. However, little is known about whether this generation benefit is preserved in cognitive aging and Alzheimer's disease and related dementias (AD/ADRD).

This study will investigate the cognitive and communicative mechanisms that support memory for information exchanged during conversation in older adults with healthy cognition and those with mild cognitive impairment (MCI) or mild Alzheimer's disease (AD). The study will examine whether information that participants actively generate during conversation is better remembered than information they receive from a conversational partner and whether communication supports, including verbal and written support, influence subsequent memory for conversational information.

The study will also investigate individual differences that may contribute to successful memory during communication. Cognitive and language measures and visual attention during conversational tasks will be examined as potential predictors of memory performance. By identifying mechanisms and communication conditions that support memory for conversational information, this research aims to improve understanding of everyday communication and memory across cognitive aging and early-stage cognitive impairment.

03

Conditions studied

  • Alzheimer Dementia (AD)
  • Mild Cognitive Impairment (MCI) Amnestic

Keywords

  • Alzheimer's disease
  • Mild cognitive impairment
  • Cognitive aging
  • Memory
  • Social communication
  • Communication support
  • Language
04

Who can participate

Ages eligible
65 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion/Exclusion criteria for both groups: Participants must be 65 years of age or older, report English as their native language (i.e., acquired English as their first language and use it as their primary language for daily communication), and demonstrate adequate hearing and vision-either uncorrected or corrected with devices (e.g., hearing aids, eyeglasses)-sufficient to participate in conversation tasks and view visual stimuli presented on a screen or in printed format (see vision and hearing screening information included in Protection of Human Subjects). All participants must be able to provide or have a legally authorized representative available if needed.
  • Additional inclusion criteria for the MCI/AD group: Participants must meet the diagnostic criteria for either 1) an amnestic form of MCI or probable Alzheimer's disease with an amnestic phenotype, as defined by McKhann et al.. Diagnosis must be confirmed by a qualified clinician and documented in the medical record or referral form. Additionally, participants must score in the mild impairment range on the -2 (MMSE-2), with scores adjusted for age and education based on published normative data.
  • Additional inclusion criteria for the healthy older adult group: Participants must 1) score at or above age- and education-adjusted population norms on the MMSE-2; 2) have no known history of dementia. All healthy older adults will complete a brief telephone or remote pre-screening conducted by trained research staff in the PI's laboratory. This process will assess eligibility and ensure demographic matching (e.g., age, gender, education) with the MCI/AD group.

Exclusion criteria

Exclusion Criteria:

  • Participants (in both groups) will be excluded if they have: 1) a history of developmental or acquired communication disorders (e.g., autism, aphasia, or dyslexia); 2) a history of psychiatric disease (e.g., schizophrenia, bipolar disorders); 3) a history of other neurological disorders other than dementia (e.g., stroke, encephalitis, traumatic brain injury), and 4) clinical depression, alcohol abuse, or substance abuse.
  • Individuals with -2 scores outside the mild impairment range, or whose profile indicates atypical or non-amnestic forms of MCI or dementia, will be excluded.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Verbal Summary → No Summary → Written Summary

    Participants receive the three communication-support conditions in the following counterbalanced order: verbal summary, no summary, and written summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.

    Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary

  • Experimental
    Written Summary → No Summary → Verbal Summary

    Participants receive the three communication-support conditions in the following counterbalanced order: written summary, no summary, and verbal summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.

    Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary

  • Experimental
    No Summary → Verbal Summary → Written Summary

    Participants receive the three communication-support conditions in the following counterbalanced order: no summary, verbal summary, and written summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.

    Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary

  • Experimental
    No Summary → Written Summary → Verbal Summary

    Participants receive the three communication-support conditions in the following counterbalanced order: no summary, written summary, and verbal summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.

    Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary

  • Experimental
    Verbal Summary → Written Summary → No Summary

    Participants receive the three communication-support conditions in the following counterbalanced order: verbal summary, written summary, and no summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.

    Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary

  • Experimental
    Written Summary → Verbal Summary → No Summary

    Participants receive the three communication-support conditions in the following counterbalanced order: written summary, verbal summary, and no summary. Participants complete a simulated health-related conversation under each condition, followed by assessment of memory for information exchanged during the conversation.

    Behavioral: Verbal Summary · Behavioral: Written Summary · Behavioral: No Summary

Interventions

  • BehavioralVerbal Summary

    Participants complete a simulated health-related conversation and are given an opportunity to summarize the content of the conversation in their own words verbally. This condition is designed to examine whether actively generating a verbal summary of information exchanged during conversation supports subsequent memory for the conversation content.

  • BehavioralWritten Summary

    Participants complete a simulated health-related conversation and are given an opportunity to summarize the content of the conversation in their own words in writing. This condition is designed to examine whether actively generating a written summary of information exchanged during conversation supports subsequent memory for the conversation content.

  • BehavioralNo Summary

    Participants complete a simulated health-related conversation without an opportunity to, verbally or in writing, summarize the conversation content. This condition serves as the comparison condition for examining the effects of verbal and written summarization on subsequent memory for information exchanged during conversation.

06

What researchers measure

Primary outcomes

  1. proportion of correctly recalled information units during conversation tasks

    Conversational memory performance will be measured as the proportion of correctly recalled information units (IUs) from structured and unstructured conversational tasks. An IU is a discrete, meaningful component of information presented during a conversation. Recall performance will be calculated by dividing the number of correctly recalled IUs by the total number of eligible IUs. Scores range from 0 to 1, with higher scores indicating better memory performance. Performance will be compared across speaking and listening conditions, across memory support strategies, and between healthy older adults and individuals with mild cognitive impairment or mild Alzheimer's disease.

    Time frame: across five weekly study visits

Secondary outcomes

  1. visual attention during conversation tasks

    Eye-tracking measures will be used to examine visual attention during conversational tasks. Gaze patterns, including fixation duration and allocation of visual attention to predefined areas of interest (e.g., faces and objects), will be analyzed to investigate relationships between attentional engagement, conversational conditions, cognitive status, and subsequent memory performance.

    Time frame: during eye-tracking conversational tasks

07

Study locations

1 site
  • Communication, Memory, and Mind Lab
    New York, New York 10012, United States
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Analytic code

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for May 2031, 52 months later.

Of 885 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 52 months is above that.

Counting every sponsor, half of 962 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Jan 2027
Primary completionEst.
May 2031
CompletionEst.
Aug 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942324
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Jan 2027 (estimated)
Primary completion
May 2031 (estimated)
Completion
Aug 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Si On Yoon, PhD
Contact
sy4195@nyu.edu
212-998-5444

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion